Navigation Links
Trial launched into curry chemical's cancer-fighting properties
Date:5/6/2012

Compounds found in curry are being investigated as a way of improving drug response in patients with advanced bowel cancer in a new study launched today (Monday).

Scientists at the Cancer Research UK and National Institute for Health Research Experimental Cancer Medicine Centre (ECMC) in Leicester will investigate whether tablets containing curcumin found in the spice turmeric can be safely added to the standard treatment for bowel cancer that has spread.

Earlier studies have shown that curcumin can enhance the ability of chemotherapy to kill bowel cancer cells in the lab.

The trial is being funded by Hope Against Cancer, The Royal College of Surgeons and the Bowel Disease Research Foundation.

Patients with advanced bowel cancer are usually given a treatment called FOLFOX, which combines three chemotherapy drugs. But around 40-60 per cent of patients don't respond and, of those who do, side effects such as severe tingling or nerve pain can limit the number of cycles patients can have.

Chief investigator Professor William Steward, ECMC director at the University of Leicester, said: "Once bowel cancer has spread it is very difficult to treat, partly because the side effects of chemotherapy can limit how long patients can have treatment. The prospect that curcumin might increase the sensitivity of cancer cells to chemotherapy is exciting because it could mean giving lower doses, so patients have fewer side effects and can keep having treatment for longer.

"This research is at a very early stage, but investigating the potential of plant chemicals to treat cancer is an intriguing area that we hope could provide clues to developing new drugs in the future."

Around 40 patients with bowel cancer that has spread to the liver will be recruited to take part in the study at Leicester Royal Infirmary and Leicester General Hospital. Three quarters of these will be given curcumin tablets for seven days, before
'/>"/>

Contact: Ailsa Stevens
44-203-469-8300
University of Leicester
Source:Eurekalert

Page: 1 2

Related biology news :

1. Sentara begins international trial -- open at only 24 US locations
2. 12-month ATLANTA trial data show sustained benefit of Catania Stent
3. First results from hospital trials testing
4. Positive results in Phase 2 trial of treatment of C-difficile-associated diarrhea
5. New filtering technology has environmental, industrial applications
6. Using water to understand human society, from the industrial revolution to global trade
7. First trial in patients with a potential treatment of the incurable ALS muscle disease
8. In just 5 years, gene discovery to clinical trial of potential treatment
9. Vitamins C and E and beta carotene again fail to reduce cancer risk in randomized controlled trial
10. Director of Berman Institute comments on FDA Approval of first human embryonic stem cell trial
11. Review of probiotic trial research finds only Bifantis able to claim efficacy for IBS symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... biotechnological company, has presented at the CIC ... (Derio), the first DNA chip concerning diagnosis ... the discrimination between normal, steatosis and NASH ... a progressive disease of the liver of ...
... system is a marvel of versatility, creating a variety of ... To carry out these tasks, immune cells follow a career ... a report in the May 2005 issue of Immunity, Fox ... Ph.D. and Dietmar J. Kappes, Ph.D., show that cell-receptor signaling ...
... of the National Institutes of Health, have built the ... Scientists searching for genes that go awry and cause ... point of reference because it pinpoints which genes are ... normal conditions, without known disease. , Scientists can compare ...
Cached Biology News:Owl genomics presents a HEPATOCHIP for diagnosis of non-alcoholic steatohepatitis 2Fox Chase study shows that weakened T-cell receptor signals change T-cell lineage 2Fox Chase study shows that weakened T-cell receptor signals change T-cell lineage 3Gov't Creates Gene Database of Normal Human Tissues 2Gov't Creates Gene Database of Normal Human Tissues 3Gov't Creates Gene Database of Normal Human Tissues 4
(Date:12/24/2014)... Nashville Fertility Center announced that ... the American Society for Reproductive Medicine (ASRM), a leading ... reproductive medicine. In his new role as treasurer, ... board and will have a voice in furthering the ... supported ASRM since 1984 when he joined while conducting ...
(Date:12/24/2014)... Texas , Dec. 23, 2014 ... company focused on gynecologic disease, announced today that ... Schuler , Birchview Fund LLC and several Vermillion ... of unregistered shares of Vermillion,s common stock and ... stock in a private placement.  ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... N.C. , Dec. 22, 2014  Alternative ... announced that it has signed a letter of ... that has developed and patented a nanotechnology-based development ... diagnostics products that enable rapid on-site collection and ... use/abuse and health issues in an immediate, non-invasive ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3ALNE Announces Intention To Acquire BioTechPharma 2
... Laboratories, pathologist, Ronald L. Weiss, MD, MBA, FCAP, received ... Pathologists at CAP ,11, the organization,s annual meeting, held ... the award honors members "who have made a broad ... of pathology." (Logo: http://photos.prnewswire.com/prnh/20110915/SF69370LOGO ) ...
... 2011 NewCardio, Inc., (OTC BB: NWCI) a cardiovascular ... Clinilabs, will utilize QTinno®, NewCardio,s automated cardiac safety solution, ... new drug under development for a central nervous system ... one important aspect of the trial. Clinilabs, ...
... 2011 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), ... announced financial results for the third quarter of 2011. For ... net loss of $4.6 million, or $0.10 per share, as ... per share, for the third quarter of 2010. As of ...
Cached Biology Technology:ARUP Laboratories' Pathologist, Ronald L. Weiss, MD, Honored With Lifetime Achievement Award for Contributions to Patient Care and Pathology 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 3Clinilabs will Conduct Phase 1 Trial Using QTinno® 4Clinilabs will Conduct Phase 1 Trial Using QTinno® 5Orexigen® Therapeutics Reports Third Quarter Financial Results 2Orexigen® Therapeutics Reports Third Quarter Financial Results 3Orexigen® Therapeutics Reports Third Quarter Financial Results 4Orexigen® Therapeutics Reports Third Quarter Financial Results 5